Innoventric

Innoventric is a structural heart medical device company primarily engaged in the development of percutaneous solutions for tricuspid regurgitation and right heart diseases. As part of its first-in-human clinical trial in Europe, Innoventric has performed over 10 implants using the promising Trillium™ technology. The company holds an extensive patent portfolio for Trillium™ and other tricuspid technologies. Trillium™ offers a unique proprietary approach to functional tricuspid valve replacement. This method easily overcomes a major hurdle of traditional valve replacement by avoiding the use of the native tricuspid valve as an anchoring point. Instead, the tubular and symmetrical vena cava serve as anchoring sites, allowing Trillium™ to work alongside the malfunctioning native valve rather than replacing it.